ABCC2基因过表达对肺腺癌预后的影响

doi:10.3969/j.issn.1000-8535.2022.06.023

广州医药 ›› 2022, Vol. 53 ›› Issue (6): 109-118.DOI: 10.3969/j.issn.1000-8535.2022.06.023

ABCC2基因过表达对肺腺癌预后的影响

方子晗^1,2, 喻祖豪¹, 刘颖³, 杨振¹, 王可^1,2

1 湖北文理学院基础医学院预防医学教研室(襄阳 441053)
2 湖北文理学院临床循证与转化医学中心(襄阳 441053)
3 广州市第一人民医院(广州 510180)

收稿日期:2022-02-03 出版日期:2022-11-20 发布日期:2022-11-30
通讯作者: 王可,E-mail: mqlhome76@163.com
基金资助:
湖北省教育厅科学技术研究计划青年人才项目(Q20212605);湖北省大学生创新训练项目(S2020105109031)

Effect of ABCC2 overexpression on prognosis of lung adenocarcinoma

FANG Zihan^1,2, YU Zuhao¹, LIU Ying³, YANG Zhen¹, WANG Ke^1,2

1 Department of Preventive Medicine,Medical College,Hubei University of Arts and Science,Xiangyang 441053,China
2 Research Centre for Evidence-Based and Translational Medicine,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Science,Xiangyang 441053,China
3 Guangzhou First People's Hospital,Guangzhou 510180,China

Received:2022-02-03 Online:2022-11-20 Published:2022-11-30

摘要/Abstract

摘要： 目的分析ABCC2基因表达水平与肺腺癌预后之间的关联性,并对其影响机制进行初步探索。方法采用TCGA数据库和HPA数据库对肺腺癌病人癌组织和癌旁组织基因表达数据进行差异性分析,单因素及多因素COX回归评估ABCC2与肺腺癌预后之间的关联性,GSEA用于探讨与ABCC2显著关联的信号通路。结果 ABCC2在肺腺癌肿瘤组织中存在过表达现象,Kaplan-Meier生存分析曲线结果显示ABCC2基因过表达使肺腺癌病人的死亡风险显著升高(HR=1.46,95%CI=1.09~1.95; P=0.010)。单因素及多因素COX回归结果显示ABCC2基因过表达是肺腺癌病人不良预后的独立危险因素。GSEA结果显示ABCC2可能通过调节药物代谢从而对肺腺癌的发展进行调控。结论 ABCC2基因过表达使肺腺癌病人的死亡风险显著升高,ABCC2可能是肺腺癌不良预后的潜在分子生物标志物。

关键词: ABCC2, 肺腺癌, 预后, TCGA数据库, GSEA

Abstract: Objective To estimate the association between ABCC2 mRNA expression and the prognosis of lung adenocarcinoma and explore the potential influencing mechanism.Methods Difference analysis was used to evaluate the gene expression in tumor tissues and adjacent normal tissues based on The Cancer Genome Atlas database and Human Protein Atlas database.Multivariate COX regression and Kaplan-Meier analysis were performed to evaluate the association between ABCC2 gene expression and the prognosis of lung adenocarcinoma.Gene-set enrichment analysis (GSEA) was performed to screen differentially enriched pathways associated with the ABCC2 high expression phenotype.Results ABCC2 was overexpressed in lung adenocarcinoma tumor tissues compared with adjacent normal tissues.Kaplan-Meier survival analysis showed a significant relationship between ABCC2 mRNA expression and lung adenocarcinoma prognosis (HR=1.16,95% CI=1.09-1.95; P=0.010).Univariate and multivariate Cox regression analysis showed that ABCC2 mRNA expression was an independent risk factor affecting the survival of patients with lung adenocarcinoma.The results of GSEA suggested that ABCC2 may influence the development of lung adenocarcinoma by regulating the metabolism of targeted drug the treatment.Conclusions ABCC2 overexpression can significantly increase the risk of death in patients with lung adenocarcinoma,ABCC2 may be a potential molecular marker for poor prognosis in lung adenocarcinoma.

Key words: ABCC2, lung adenocarcinoma, prognosis, TCGA database, GSEA

方子晗, 喻祖豪, 刘颖, 杨振, 王可. ABCC2基因过表达对肺腺癌预后的影响[J]. 广州医药, 2022, 53(6): 109-118.

FANG Zihan, YU Zuhao, LIU Ying, YANG Zhen, WANG Ke. Effect of ABCC2 overexpression on prognosis of lung adenocarcinoma[J]. Guangzhou Medical Journal, 2022, 53(6): 109-118.

参考文献

[1] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
[2] ARRITETA O,LAZCANO E. Lung cancer.Epidemiology,diagnosis and treatment[J].Salud Publica Mex,2019,61(3): 217-218.
[3] ALEXANDER M,KIM S Y,CHENG H. Update 2020: Management of Non-Small Cell Lung Cancer[J].Lung,2020,198(6):897-907.
[4] 刘盈,黄凤祥,陈红杰,等. 基于数据库挖掘UBE2C在肺腺癌中的表达及其临床意义[J].中南大学学报(医学版),2020,45(9):1044-1052.
[5] FOIS S S,PALIOGIANNIS P,ZINELLU A,et al.Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer[J].Int J Mol Sci,2021,22(2):612.
[6] HUANG Y S,CHANG T E,PERNG C L,et al.The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia[J].J Chin Med Assoc,2021,84(2):129-135.
[7] WISSEL G,DENG F,KUDRYAVTSEV P,et al.A structure-activity relationship study of ABCC2 inhibitors[J].Eur J Pharm Sci,2017(103):60-69.
[8] CHEN Y,ZHOU H,YANG S,et al.Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer[J].Cell Biochem Funct,2021,39(2):277-286.
[9] WEI D,ZHANG H,PENG R,et al.ABCC2 (1249G>A) polymorphism implicates altered transport activity for sorafenib[J].Xenobiotica,2017,47(11):1008-1014.
[10] DIGRE A,LINDSKOG C. The Human Protein Atlas-Spatial localization of the human proteome in health and disease[J].Protein Sci,2021,30(1):218-233.
[11] GEISTLINGER L,CSABA G,SANTARELLI M,et al.Toward a gold standard for benchmarking gene set enrichment analysis[J].Brief Bioinform,2021,22(1):545-556.
[12] CLARKE M F,DICK J E,DIRKS P B,et al.Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells[J].Cancer Res,2006,66(19):9339-9344.
[13] DEAN M. ABC transporters,drug resistance,and cancer stem cells[J].J Mammary Gland Biol Neoplasia,2009,14(1):3-9.
[14] KORITA P V,WAKAI T,SHIRAI Y,et al.Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma[J].Oncol Rep,2010,23(4):965-972.
[15] BÜCHLER M,KÖNIG J,BROM M,et al.cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein,cMrp,reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats[J].J Biol Chem,1996,271(25):15091-15098.
[16] SUZUKI H,SUGIYAMA Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition[J].Adv Drug Deliv Rev,2002,54(10):1311-1331.
[17] ROST D,MAHNER S,SUGIYAMA Y,et al.Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine[J].Am J Physiol Gastrointest Liver Physiol,2002,282(4):G720-G726.
[18] ITO K,OLESCHUK C J,WESTLAKE C,et al.Mutation of Trp1254 in the multispecific organic anion transporter,multidrug resistance protein 2 (MRP2) (ABCC2),alters substrate specificity and results in loss of methotrexate transport activity[J].J Biol Chem,2001,276(41):38108-38114.
[19] LIU Y,YIN Y,SHENG Q,et al.Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia[J].PLoS One,2014,9(1):e82681.
[20] ANDERSEN V,VOGEL L K,KOPP T I,et al.High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence[J].PLoS One,2015,10(3):e0119255.
[21] KUMAR A,JAITAK V. Natural products as multidrug resistance modulators in cancer[J].Eur J Med Chem,2019(176):268-291.
[22] QIAN L,FANG S,YAN Y L,et al.The ABCC2 c. -24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis[J].J Clin Neurosci,2017(37):6-14.
[23] KARTAL-YANDIM M,ADAN-GOKBULUT A,BARAN Y. Molecular mechanisms of drug resistance and its reversal in cancer[J].Crit Rev Biotechnol,2016,36(4):716-726.
[24] SHARIFI M J,BAHOUSH G,ZAKER F,et al.Association of -24CT,1249GA,and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia[J].Pediatr Hematol Oncol,2014,31(2):169-177.
[25] SUN L,KE J,HE Z,et al.HES1 Promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins[J].J Cancer,2017,8(14):2802-2808.
[26] ZHANG D,DING L,LI Y,et al.Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumor cells[J].Sci Rep,2017,7(1):16231.
[27] CAO K N,REN G H,LU C C,et al.ABCC2 c. -24 C>T sing- le-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects[J].Eur J Clin Pharmacol,2020,76(1):51-59.
[28] 潘霞,王智慧,雷小勇. microRNAs与ABC转运蛋白介导的肿瘤多药耐药研究进展[J].中华肿瘤防治杂志,2015,22(8):644-648.
[29] CHEN Y,ZHOU H,YANG S,et al.Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer[J].Cell Biochem Funct,2021,39(2):277-286.
[30] CUFFE S,AZAD A K,QIU X,et al.ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung cancer patients[J].Cancer Epidemiol,2016(41):50-56.

ABCC2基因过表达对肺腺癌预后的影响

Effect of ABCC2 overexpression on prognosis of lung adenocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王建, 彭芳, 王志, 孙雪骐. 胃肠道套细胞淋巴瘤的临床病理学特点分析及预后影响因素分析[J]. 广州医药, 2022, 53(6): 133-137.
[2]	陈婷女, 梁慕琼, 梁亮. 儿童重症肺炎支气管肺泡灌洗液病原学及疾病预后分析[J]. 广州医药, 2022, 53(3): 53-56.
[3]	刘颖, 方子晗, 张雅琴, 王可. DNA甲基化位点对肺腺癌预后的作用研究[J]. 广州医药, 2022, 53(3): 112-117.
[4]	王俊, 闫娅, 李永红, 李佳. 分析CT肺动脉栓塞指数与急性肺栓塞患者右心功能及预后的相关性[J]. 广州医药, 2022, 53(2): 120-123.
[5]	吴天源, 罗义, 吕磊, 谭文亮, 孙少喜. CYP2C19基因多态性与急性心肌梗死患者炎症指标、临床预后的相关性[J]. 广州医药, 2022, 53(1): 1-5.
[6]	陶豫东. 益生菌结合肠内营养干预纠正缺血性急性脑卒中患者肠道菌落紊乱的作用及对其预后的影响[J]. 广州医药, 2022, 53(1): 109-113.
[7]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[8]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[9]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[10]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[11]	钟玲. Napsin A、TTF-1及CK7在恶性胸水中对肺腺癌的诊断价值[J]. 广州医药, 2021, 52(2): 66-69.
[12]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[13]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[14]	梁春艳. 二氢丹参酮I在胃癌AGS细胞中作用机制的生物信息学分析[J]. 广州医药, 2020, 51(2): 85-93.
[15]	李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.